BPC-157/TB500 3mg/3mg/mL (5mL)

BPC-157/TB500 3 mg/3 mg/mL (5 mL) refers to a research peptide blend combining Body Protection Compound-157 (BPC-157) and TB-500 (a fragment of Thymosin Beta-4) in a solution for laboratory or investigational use. These peptides are widely discussed in preclinical research for their potential roles in tissue repair, healing, and regeneration, but they are not approved by the U.S. Food and Drug Administration (FDA) for medical use in humans and are typically sold as “research chemicals.” BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in gastric juice. In animal models, it has shown the ability to promote angiogenesis (formation of new blood vessels), support tendon and ligament healing, and modulate inflammatory pathways. These effects have been demonstrated in rodent studies of tendon-to-bone healing and soft tissue recovery. TB-500 is a synthetic segment of Thymosin Beta-4 that is believed to enhance cell migration, cytoskeletal flexibility, and wound repair mechanisms, potentially aiding systemic tissue regeneration. When combined, the two peptides are often referred to in the peptide community as a “Wolverine Stack,” with proponents suggesting they may offer broader support for injury recovery, reduced inflammation, and improved structural resilience compared with either peptide alone. However, robust human clinical evidence is lacking, and expert sources caution that benefits are speculative and risks—such as unregulated product quality and unknown long-term effects—are real. Links for more information: BPC-157 and TB-500 healing mechanisms: https://www.peptidesciences.com/bpc-157-tb-500-blend Peptide duo overview (“Wolverine Stack”): https://www.savingfaceaustin.com/blog/bpc-157-tb500-the-peptide-duo-for-next-level-healing/ Research background and angiogenesis effects: https://globalrph.com/2025/11/bpc-157-and-tb-500-background-indications-efficacy-and-safety/